~~U.S.~~ UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~Report~~report (date of earliest event reported): ~~July~~November 1015, 2012

~~Medisafe~~MEDIASAFE 1 ~~Technologies~~TECHNOLOGIES ~~Corp~~CORP.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in its ~~charter~~Charter)

~~Delaware~~Commission File No.: 333-161914

(State or other jurisdiction of incorporation)

Delaware	46-0523031
(State of Incorporation)	(I.R.S. Employer Identification No.)

5a Hataltan Street, Jerusalem, Israel	96926
(Address of Principal Executive Offices)	(ZIP Code)

333-161914	46-0523031
(Commission File No.)	(IRS Employer Identification No.)

Registrant's Telephone Number, including area code: +972-77-3318877

~~c/o~~Check ~~Jacob~~the ~~Elhadad~~appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

5A¨ Written communications ~~Hataltan~~pursuant ~~Street~~to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Jerusalem~~Item ,1.01 ~~Israel~~Entry ~~96926~~Into a Material Definitive Agreement.

~~Phone~~On ~~Number~~November ~~972~~15, 2012, Medisafe 1 Technologies Corp., a Delaware corporation (the "Registrant" or "Medisafe"), entered into a license agreement (the "License Agreement") with Safecode Drug Technologies Corp., a Delaware corporation and a public reporting company engaged in the medical technology business ("Safecode"). Pursuant to the License Agreement, Medisafe, as licensor, granted Safecode, as licensee, a non -77 exclusive license to manufacture, market and otherwise commercially exploit world-~~3318877~~wide Medisafe's patented device for administering medicine in correct dosages to the correct patients. The License Agreement provides that as consideration for the license, Safecode will issue to Medisafe ten million shares of its common stock valued at $.70 per share. the License Agreement provides for certain adjustments in the event that Safecode's shares are not equal to or greater than that price twelve months after the effective date. The License Agreement is attached hereto as Exhibit 99.1.

~~Fax~~Item ~~number~~9.01 ~~972-77-3318879~~Financial Statements and Exhibits

(~~Address~~b) ~~and~~The ~~telephone~~following ~~number~~documents ofare ~~principal~~filed by the Registrant as exhibits ~~executive~~to ~~offices~~this ~~and~~current ~~place~~report ofon ~~business)~~Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

(former name or former address, if changed since last report)

Exhibit No.		Description
99.1		License Agreement between the Registrant and Safecode Drug Technologies Corp. dated November 15, 2012, filed herewith.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below)SIGNATURES

~~¨ Written~~Pursuant ~~communications pursuant~~ to ~~Rule~~the ~~425~~requirements ~~under~~of the Securities Exchange Act of ~~(17~~1934, ~~CFR~~the ~~230~~Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~425)~~

~~¨ Soliciting~~Medisafe ~~material~~1 ~~pursuant~~Technologies toCorp. ~~Rule~~By: ~~14a-12~~/s/ ~~under~~Jacob ~~the~~Elhadad ~~Exchange~~Name: ~~Act~~Jacob ~~(17~~Elhadad ~~CFR~~Title: ~~240.14-12)~~President Date: November 15, 2012

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13ed-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02 Unregistered Sales of Equity Securities

On July 10, 2012 the Registrant issued a total of 100,000,000 shares of additional common stock of the Issuer, 50,000,000 to Jacob Elhadad, President of the Issuer and 50,000,000 to Yisrael Gottlieb CFO and Secretary of the Issuer . The shares of common stock were issued as additional 2012 compensation pursuant to an agreement between the Issuer and Mr. Elhadad, and Mr Yisrael Gotlieb concurrent and due to the drop in the share value of the shares since the original issuance in January for the 2012 annual compensation.

The shares were issued without registration under Section 5 of the Securities Act of 1933 in reliance on the exemption from registration contained in Section 4(2) of the Securities Act.

Section 5 -- Corporate Governance and Management

Item 5.03 Amendments to Articles of Incorporation or Bylaws, Change in Fiscal Year.

On or about September 30, 2011, the Company received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50.1 % of the total issued and outstanding shares of voting stock of the Company approving a Certificate of Amendment to the Certificate of Incorporation of the Company, pursuant to which the Company will change , increase the authorized capital of the Company to a total of 1,000,000,000 shares of common stock with a par value of $0.0001 per share.

The Company however only or about May 16 , 2012, filed with the Secretary of the State of Delaware to increase the authorized capital of the Corporation to be 1,000,000,000 shares of common stock, par value of $0.0001. The filing was initiated at this time, due to the necessity of the agreements with Asher Enterprises and the associated convertible loans and convertible loan document requirements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 20, 2012

	Medisafe 1 Technologies Corp.
	By:	Jacob Elhadad
		Jacob Elhadad
		Title: President and Director (Principal Executive Officer)

Filing Compare · MEDISAFE 1 TECHNOLOGIES CORP